Top

BMC Neurology

Published in:

Open Access 01-12-2023 | Alzheimer's Disease | Research

Meta-analysis and systematic review of peripheral platelet-associated biomarkers to explore the pathophysiology of alzheimer's disease

Authors: Jiajia Fu, Xiaohui Lai, Yan Huang, Ting Bao, Jing Yang, Sihui Chen, Xueping Chen, Huifang Shang

Published in: BMC Neurology | Issue 1/2023

Abstract

Introduction

Platelets are the primary peripheral reserve of amyloid precursor protein (APP), providing more than 90% of blood amyloid-beta (Aβ). Some oxidative stress markers and neurotransmitter markers were also differentially expressed in the peripheral platelets of AD. Therefore, the present study explored the differences in platelet-associated biomarkers between AD and healthy controls using meta-analysis and systematic review to reveal the value of platelet in the pathogenesis and development of AD.

Methods

We searched all the related studies that probed into the platelets in AD based on PubMed, Embase, and web of science databases from the establishment to November 04, 2021.

Results

Eighty-eight studies were included in the meta-analysis, and the platelets data of 702 AD and 710 controls were analyzed. The results of standardized mean difference (SMD) showed that platelets in AD had lower levels of APP ratio (SMD: -1.89; p < 0.05), ADAM10 (SMD: -1.16; p < 0.05), Na + -K + -ATPase (SMD: -7.23; p < 0.05), but higher levels of HMW/LMW tau (SMD: 0.92; p < 0.05), adenosine A₂ receptor (SMD: 4.27; p < 0.05), MAO-B (SMD: 1.73; p < 0.05), NO (SMD: 4.25; p < 0.05) and ONOO⁻ (SMD: 7.33; p < 0.05). In the systematic review, some other platelet markers seem to be meaningful in AD patients.

Conclusion

The results of the present meta-analysis and systematic review demonstrated that the alterations of APP metabolic enzymes, oxidative stress markers, and neurotransmitter factors in platelets were similar to their changes in the central nervous system of AD, suggesting that platelet could be a good source of peripheral biomarkers and may play an important role in the pathophysiological development of AD.

Available only for authorised users

Kirson NY, Desai U, Ristovska L, et al. Assessing the economic burden of Alzheimer’s disease patients first diagnosed by specialists. BMC Geriatr. 2016;16:138. https://doi.org/10.1186/s12877-016-0303-5. (Published 2016 July 11).CrossRefPubMedPubMedCentral

Patterson C. Alzheimer’s Disease International. London: World Alzheimer report; 2018.

Reinhard C, Hébert SS, De Strooper B. The amyloid-beta precursor protein: integrating structure with biological function. EMBO J. 2005;24(23):3996–4006. https://doi.org/10.1038/sj.emboj.7600860.CrossRefPubMedPubMedCentral

Tang K, Hynan LS, Baskin F, Rosenberg RN. Platelet amyloid precursor protein processing: a bio-marker for Alzheimer’s disease. J Neurol Sci. 2006;240(1–2):53–8. https://doi.org/10.1016/j.jns.2005.09.002.CrossRefPubMed

Diniz BS, Pinto Júnior JA, Forlenza OV. Do CSF total tau, phosphorylated tau, and beta-amyloid 42 help to predict progression of mild cognitive impairment to Alzheimer’s disease? A systematic review and meta-analysis of the literature. World J Biol Psychiatry. 2008;9(3):172–82. https://doi.org/10.1080/15622970701535502.CrossRefPubMed

Zainaghi IA, Forlenza OV, Gattaz WF. Abnormal APP processing in platelets of patients with Alzheimer’s disease: correlations with membrane fluidity and cognitive decline. Psychopharmacol. 2007;192(4):547–53. https://doi.org/10.1007/s00213-007-0748-5.CrossRef

Bermejo-Bescós P, Martín-Aragón S, Jiménez-Aliaga K, et al. Processing of the platelet amyloid precursor protein in the mild cognitive impairment (MCI). Neurochem Res. 2013;38(7):1415–23. https://doi.org/10.1007/s11064-013-1039-7.CrossRefPubMed

Zubenko GS, Huff FJ, Beyer J, Auerbach J, Teply I. Familial risk of dementia associated with a biologic subtype of Alzheimer’s disease. Arch Gen Psychiatry. 1988;45(10):889–93. https://doi.org/10.1001/archpsyc.1988.01800340011001.CrossRefPubMed

Vignini A, Nanetti L, Moroni C, et al. Modifications of platelet from Alzheimer disease patients: a possible relation between membrane properties and NO metabolites. Neurobiol Aging. 2007;28(7):987–94. https://doi.org/10.1016/j.neurobiolaging.2006.05.010.CrossRefPubMed

10.

Butterfield DA. beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer’s disease. Chem Res Toxicol. 1997;10(5):495–506. https://doi.org/10.1021/tx960130e.CrossRefPubMed

11.

Kawamoto EM, Munhoz CD, Glezer I, et al. Oxidative state in platelets and erythrocytes in aging and Alzheimer’s disease. Neurobiol Aging. 2005;26(6):857–64. https://doi.org/10.1016/j.neurobiolaging.2004.08.011.CrossRefPubMed

12.

Yu Jie, Jia Jian-ping. Platelet function in patients with Alzheimer disease: analysis of 40 cases. Zhonghua Yi Xue Za Zhi. 2009;89:183–6.PubMed

13.

Garcia-Alloza M, Gil-Bea FJ, Diez-Ariza M, et al. Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer’s disease. Neuropsychologia. 2005;43(3):442–9. https://doi.org/10.1016/j.neuropsychologia.2004.06.007.CrossRefPubMed

14.

Racchi M, Govoni S. The pharmacology of amyloid precursor protein processing. Exp Gerontol. 2003;38(1–2):145–57. https://doi.org/10.1016/s0531-5565(02)00158-4.CrossRefPubMed

15.

Camacho A, Dimsdale JE. Platelets and psychiatry: lessons learned from old and new studies. Psychosom Med. 2000;62(3):326–36. https://doi.org/10.1097/00006842-200005000-00006.CrossRefPubMed

16.

Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. Available from: URL: http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm [cited 2009 Oct 19]

17.

Shi Y, Gu L, Alsharif AA, Zhang Z. The Distinction of Amyloid-β Protein Precursor (AβPP) Ratio in Platelet Between Alzheimer’s Disease Patients and Controls: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2017;59(3):1037–44. https://doi.org/10.3233/JAD-170253.CrossRefPubMed

18.

Evin G, Zhu A, Holsinger RM, Masters CL, Li QX. Proteolytic processing of the Alzheimer’s disease amyloid precursor protein in brain and platelets. J Neurosci Res. 2003;74(3):386–92. https://doi.org/10.1002/jnr.10745.CrossRefPubMed

19.

Baskin F, Rosenberg RN, Iyer L, Hynan L, Cullum CM. Platelet APP isoform ratios correlate with declining cognition in AD. Neurology. 2000;54(10):1907–9. https://doi.org/10.1212/wnl.54.10.1907.CrossRefPubMed

20.

Tyler SJ, Dawbarn D, Wilcock GK, Allen SJ. alpha- and beta-secretase: profound changes in Alzheimer’s disease. Biochem Biophys Res Commun. 2002;299(3):373–6. https://doi.org/10.1016/s0006-291x(02)02635-9.CrossRefPubMed

21.

Manzine PR, de França Bram JM, Barham EJ, et al. ADAM10 as a biomarker for Alzheimer’s disease: a study with Brazilian elderly. Dement Geriatr Cogn Disord. 2013;35(1–2):58–66. https://doi.org/10.1159/000345983.CrossRefPubMed

22.

Johnston JA, Liu WW, Todd SA, et al. Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer’s disease. Biochem Soc Trans. 2005;33(Pt 5):1096–100. https://doi.org/10.1042/BST20051096.CrossRefPubMed

23.

Zimmermann M, Borroni B, Cattabeni F, Padovani A, Di Luca M. Cholinesterase inhibitors influence APP metabolism in Alzheimer disease patients. Neurobiol Dis. 2005;19(1–2):237–42. https://doi.org/10.1016/j.nbd.2005.01.002.CrossRefPubMed

24.

Fukumoto H, Cheung BS, Hyman BT, Irizarry MC. Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol. 2002;59(9):1381–9. https://doi.org/10.1001/archneur.59.9.1381.CrossRefPubMed

25.

Borroni B, Agosti C, Marcello E, Di Luca M, Padovani A. Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets. Exp Gerontol. 2010;45(1):53–6.CrossRefPubMed

26.

Liu X, Liu Y, Ji S. Secretases Related to Amyloid Precursor Protein Processing. Membranes (Basel). 2021;11(12):983. https://doi.org/10.3390/membranes11120983. (Published 2021 Dec 15).CrossRefPubMedPubMedCentral

27.

Bram JMF, Talib LL, Joaquim HPG, Sarno TA, Gattaz WF, Forlenza OV. Protein levels of ADAM10, BACE1, and PSEN-1 in platelets and leukocytes of Alzheimer’s disease patients. Eur Arch Psychiatry Clin Neurosci. 2019;269(8):963–72. https://doi.org/10.1007/s00406-018-0905-3.CrossRefPubMed

28.

Maccioni RB, Farías G, Morales I, Navarrete L. The revitalized tau hypothesis on Alzheimer’s disease. Arch Med Res. 2010;41(3):226–31. https://doi.org/10.1016/j.arcmed.2010.03.007.CrossRefPubMed

29.

Farías G, Pérez P, Slachevsky A, Maccioni RB. Platelet tau pattern correlates with cognitive status in Alzheimer’s disease. J Alzheimers Dis. 2012;31(1):65–9. https://doi.org/10.3233/JAD-2012-120304.CrossRefPubMed

30.

Guzmán-Martínez L, Tapia JP, Farías GA, González A, Estrella M, Maccioni RB. The Alz-tau Biomarker for Alzheimer’s Disease: Study in a Caucasian Population. J Alzheimers Dis. 2019;67(4):1181–6. https://doi.org/10.3233/JAD-180637.CrossRefPubMed

31.

Teunissen CE, Lütjohann D, von Bergmann K, et al. Combination of serum markers related to several mechanisms in Alzheimer’s disease. Neurobiol Aging. 2003;24(7):893–902. https://doi.org/10.1016/s0197-4580(03)00005-8.CrossRefPubMed

32.

Muriel P, Castañeda G, Ortega M, Noël F. Insights into the mechanism of erythrocyte Na+/K+-ATPase inhibition by nitric oxide and peroxynitrite anion. J Appl Toxicol. 2003;23(4):275–8. https://doi.org/10.1002/jat.922.CrossRefPubMed

33.

Varadarajan S, Yatin S, Aksenova M, Butterfield DA. Review: Alzheimer’s amyloid beta-peptide-associated free radical oxidative stress and neurotoxicity. J Struct Biol. 2000;130(2–3):184–208. https://doi.org/10.1006/jsbi.2000.4274.CrossRefPubMed

34.

Behl T, Kaur D, Sehgal A, et al. Role of Monoamine Oxidase Activity in Alzheimer’s Disease: An Insight into the Therapeutic Potential of Inhibitors. Molecules. 2021;26(12):3724. https://doi.org/10.3390/molecules26123724. (Published 2021 Jun 18).CrossRefPubMedPubMedCentral

35.

Ramsay RR. Molecular aspects of monoamine oxidase B. Prog Neuropsychopharmacol Biol Psychiatry. 2016;69:81–9. https://doi.org/10.1016/j.pnpbp.2016.02.005.CrossRefPubMed

36.

Oreland L. Platelet monoamine oxidase, personality and alcoholism: the rise, fall and resurrection. Neurotoxicology. 2004;25(1–2):79–89. https://doi.org/10.1016/S0161-813X(03)00115-3.CrossRefPubMed

37.

Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol Rev. 2018;98(3):1591–625. https://doi.org/10.1152/physrev.00049.2017.CrossRefPubMed

38.

Canas PM, Porciúncula LO, Cunha GM, et al. Adenosine A2A receptor blockade prevents synaptotoxicity and memory dysfunction caused by beta-amyloid peptides via p38 mitogen-activated protein kinase pathway. J Neurosci. 2009;29(47):14741–51. https://doi.org/10.1523/JNEUROSCI.3728-09.2009.CrossRefPubMedPubMedCentral

39.

Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J. 2001;20(1–2):27–39. https://doi.org/10.1093/emboj/20.1.27.CrossRefPubMedPubMedCentral

Title: Meta-analysis and systematic review of peripheral platelet-associated biomarkers to explore the pathophysiology of alzheimer's disease
Authors: Jiajia Fu
Xiaohui Lai
Yan Huang
Ting Bao
Jing Yang
Sihui Chen
Xueping Chen
Huifang Shang
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Alzheimer's Disease
Alzheimer's Disease
Biomarkers
Published in: BMC Neurology / Issue 1/2023
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-023-03099-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Meta-analysis and systematic review of peripheral platelet-associated biomarkers to explore the pathophysiology of alzheimer's disease

Abstract

Introduction

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2023

High-dose pharmaceutical-grade biotin in patients with demyelinating neuropathies: a phase 2b open label, uncontrolled, pilot study

Serum LDH levels may predict poor neurological outcome after aneurysmal subarachnoid hemorrhage

Clinical value of the low-grade inflammation score in aneurysmal subarachnoid hemorrhage

Stability of sensor-based gait parameters reassessed after a period of one year in people with multiple sclerosis

Incidence and risk factors for postoperative delirium after head and neck cancer surgery: an updated meta-analysis

Predictors of severity and outcome of multiple sclerosis relapses